282 related articles for article (PubMed ID: 9597160)
21. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
22. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates and connexin 43: a critical review of evidence.
Sadr-Eshkevari P; Ashnagar S; Rashad A; Dietz M; Jackowski J; Abdulazim A; Prochnow N
Cell Commun Adhes; 2014 Oct; 21(5):241-7. PubMed ID: 24946183
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Russell RG; Watts NB; Ebetino FH; Rogers MJ
Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Feher A; Koivunemi A; Koivunemi M; Fuchs RK; Burr DB; Phipps RJ; Reinwald S; Allen MR
Bone; 2010 Jan; 46(1):203-7. PubMed ID: 19857619
[TBL] [Abstract][Full Text] [Related]
28. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonates in the treatment of disorders of mineral metabolism.
Singer FR; Minoofar PN
Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
31. Experimental basis for the use of bisphosphonates in Paget's disease of bone.
Fleisch H
Clin Orthop Relat Res; 1987 Apr; (217):72-8. PubMed ID: 3549097
[TBL] [Abstract][Full Text] [Related]
32. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
33. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
34. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
Luckman SP; Coxon FP; Ebetino FH; Russell RG; Rogers MJ
J Bone Miner Res; 1998 Nov; 13(11):1668-78. PubMed ID: 9797474
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
Roelofs AJ; Thompson K; Ebetino FH; Rogers MJ; Coxon FP
Curr Pharm Des; 2010; 16(27):2950-60. PubMed ID: 20722616
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
Kaiser T; Teufel I; Geiger K; Vater Y; Aicher WK; Klein G; Fehm T
Breast Cancer Res Treat; 2013 Jul; 140(1):35-48. PubMed ID: 23807419
[TBL] [Abstract][Full Text] [Related]
37. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
38. Clinical effects of bisphosphonates in involutional osteoporosis.
Ott SM
J Bone Miner Res; 1993 Dec; 8 Suppl 2():S597-606. PubMed ID: 8122531
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates: expanded roles in the treatment of patients with cancer.
Viale PH; Sanchez Yamamoto D
Clin J Oncol Nurs; 2003; 7(4):393-401. PubMed ID: 12929272
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Fournier P; Boissier S; Filleur S; Guglielmi J; Cabon F; Colombel M; Clézardin P
Cancer Res; 2002 Nov; 62(22):6538-44. PubMed ID: 12438248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
